Summary
Osteoarthritis is the most frequently encountered form of arthritis worldwide. Pharmacological therapies consisting of nonsteroidal anti-inflammatory drugs (NSAIDs) and analgesics such as paracetamol (acetaminophen), codeine and dextropropoxyphene are the principal means of symptom control. Osteoarthritis appears to have little impact on the pharmacokinetics of these drugs per se. However, other clinical features commonly associated with patients with osteoarthritis, such as advanced age, obesity or concurrent diseases and medications, may be important.
A limited number of concentration-response studies have demonstrated the existence of a pharmacokinetic/pharmacodynamic relationship for these drugs. However, the information derived from patients with osteoarthritis is very limited. Simple analgesics have been shown to be as effective as NSAIDs in some studies. Furthermore, the response does not appear to be able to be predicted on the basis of clinical features of inflammation.
It appears that a defined concentration-toxicity relationship exists and should be considered when dosage regimens for patients are formulated. Symptoms occur with a circadian rhythm, and similarly, there is circadian variation in the pharmacokinetic/pharmacodynamic response of a number of NSAIDs in patients with osteoarthritis. Selection of the optimal drug formulation will also be influenced by the need for continuous or intermittent therapy in these patients.
Similar content being viewed by others
References
Abernethy DR, Greenblatt DJ. Pharmacokinetics of drugs in obesity. Clinical Pharmacokinetics 7: 108–124, 1982
Abernethy DR, Greenblatt DJ. Ibuprofen disposition in obesity. Arthritis and Rheumatism 28: 1117–1121, 1985
Adams SS. Non-steroidal, anti-inflammatory drugs, plasma half-lives, and adverse reactions. Lancet 2: 1204–05, 1987
Al Arfag A, Davis P. Osteoarthritis 1991: Current drug treatment regimens. Drugs 41: 193–201, 1991
Altman RD. Laboratory findings in osteoarthritis. In Moskowitz et al. (Eds) Osteoarthritis: diagnosis and medical/surgical management, 2nd ed., pp. 313–328, WB Saunders, Philadelphia, 1992
Avgerinos A, Hutt AJ. Interindividual variability in the enantiomeric disposition of ibuprofen following the oral administration of the racemic drug to healthy volunteers. Chirality 2: 249–256, 1990
Batchlor EE, Paulus HE. Principles of drug therapy. In Moskowitz et al. (Eds) Osteoarthritis: diagnosis and medical/surgical management, 2nd ed, pp. 465–492, WB Saunders, Philadelphia, 1992
Bollet AJ. Analgesic and anti-inflammatory drugs in the therapy of osteoarthritis. Seminars in Arthritis and Rheumatism 11 (Suppl. 1): 130–132, 1981
Bradley JD, Brandt KD, Katz BP, Kalasinski LA, Ryan SI. Comparison of an antiinflammatory dose of ibuprofen, and analgesic dose of ibuprofen, and acetaminophen in the treatment of patients with osteoarthritis of the knee. New England Journal of Medicine 325: 87–91, 1991
Borda IT. The spectrum of adverse gastrointestinal effects associated with nonsteroidal anti-inflammatory drugs. In Borda & Koff (Eds) NSAIDs: a profile of adverse effects, pp. 25–80, Hanley & Belfus Inc., Philadelphia, 1992
Bradley JD, Brandt KD, Katz BP, Kalasinski LA, Ryan SI. Treatment of knee osteoarthritis: relationship of clinical features of joint inflammation to the response to a nonsteroidal antiinflammatory drug or pure analgesic. Journal of Rheumatology 19: 1950–1954, 1992a
Bradley JD, Rudy AC, Katz BP, Ryan SI, Kalasinski LA, et al. Correlation of serum concentrations of ibuprofen stereoisomers with clinical response in the treatment of hip and knee osteoarthritis. Journal of Rheumatology 19: 130–134, 1992b
Brocks DR, Jamali F. Clinical pharmacokinetics of ketorolac tromethamine. Clinical Pharmacokinetics 23: 415–427, 1992
Bruguerolle B, Desnuelle C, Jadot G, Valli M, Aquaviva PC. Chronopharmacocinétique de l’indométhacine à effet prolongé en pathologie rhumatismale. Revue International du Rhumatisme 13: 263–267, 1983
Carson JL, Strom BL, Soper KA, West SL, Morse ML. The association of nonsteroidal anti-inflammatory drugs with upper gastrointestinal tract bleeding. Archives of Internal Medicine 147: 85–88, 1987
Clench J, Reinberg A, Dziewanowska Z, Ghata J, Smolensky M. Circadian changes in the bioavailability and effects of indomethacin in healthy subjects. European Journal of Clinical Pharmacology 20: 359–369, 1981
Day RO, Furst DE, Dromgoole SH, Kramm B, Roe R, et al. Relationship of serum naproxen concentration to efficacy in rheumatoid arthritis. Clinical Pharmacology and Therapeutics 31: 733–740, 1982
Day RO, Nguyen T, Williams KM. Tenoxicam dose concentration response relationship in rheumatoid arthritis. Abstract. Clinical Pharmacology and Therapeutics 53: 152, 1993
D’Arienzo M, Pennisi M, Zanolo G, Borsa M. Ketoprofen lysine: ketoprofen serum levels and analgesic activity. Drugs in Experimental and Clinical Research 10: 863–866, 1984
Desmeules J, Dayer P, Gascon MP, Magistris M. Impact of genetic and environmental factors on codeine analgesia. Abstract. Clinical Pharmacology and Therapeutics 45: 122, 1989
Eason CT, Bonner FW, Parke DV. The importance of pharmacokinetic and receptor studies in drug safety evaluation. Regulatory Toxicology and Pharmacology 11: 288–307, 1990
Forrest JAH, Clements JA, Prescott LF. Clinical pharmacokinetics of paracetamol. Clinical Pharmacokinetics 7: 93–107, 1982
Furst DE. Clinical significance of long versus short serum half-life in NSAIDs. In Famaey & Paulus (Eds) Therapeutic applications of NSAIDs, pp. 359–372, Marcel Dekker, New York, 1992
Ghosh P, Smith M, Wells C. Second-line agents in osteoarthritis. In Dixon & Furst (Eds) Second-line agents in the treatment of rheumatic diseases, pp. 363–427, Marcel Dekker, New York, 1992
Gonzalez FJ, Meyer VA. Molecular genetics of the debrisquin-sparteine polymorphism. Clinical Pharmacology and Therapeutics 50: 233–238, 1991
Grennan DM, Aarons L, Siddiqui M, Richards M, Thompson R, et al. Dose-response study with ibuprofen in rheumatoid arthritis: clinical and pharmacokinetic findings. British Journal of Clinical Pharmacology 15: 311–316, 1983
Guissou P, Cuisinaud G, Lorca G, Lejeune E, Sassard J. Chronopharmacokinetic study of a prolonged release form of indomethacin. European Journal of Clinical Pharmacology 24: 667–670, 1983
Hamdy RC, Murnane B, Perera N, Woodcock K, Koch IM. The pharmacokinetics of benoxaprofen in elderly subjects. European Journal of Rheumatology and Inflammation 5: 69–75, 1982
Jacobs J, Goldstein AG, Kelly ME, Bloom BS. NSAID dosing schedule and compliance. Drug Intelligence and Clinical Pharmacy 22: 727–728, 1988
Kamal A, Koch IM. Pharmacokinetic studies of benoxaprofen in geriatric patients. European Journal of Rheumatology and Inflammation 5: 76–81, 1982
Kohler G, Primbs P, Morand J, Rubelt CH. Correlation between ketoprofen plasma levels and analgesic effect in acute lumbar pain and radicular pain. Clinical Rheumatology 4: 399–404, 1985
Laska EM, Sunshine A, Marrero I. The correlation between blood levels of ibuprofen and clinical analgesic response. Clinical Pharmacology and Therapeutics 40: 1–7, 1986
Lawrence JS, Bremner JM, Bier F. Osteo-arthrosis. Prevalence in the population and relationship between symptoms and x-ray changes. Annals of Rheumatic Diseases 25: 1–24, 1966
Lawrence RC, Hochberg MC, Kelsey JL, McDuffie FC, Medsger Jr TA, et al. Estimates of the prevalence of selected arthritic and musculoskeletal diseases in the United States. Journal of Rheumatology 16: 427–441, 1989
Levi F, Le Louarn C, Reinberg A. Chronotherapy of osteoarthritic patients: optimization of indomethacin sustained release (ISR). Annual Review of Chronopharmacology 1: 345–348, 1984
Lin JH, Cocchetto DM, Duggan DE. Protein binding as a primary determinant of the clinical pharmacokinetic properties of non-steroidal anti-inflammatory drugs. Clinical Pharmacokinetics 12: 402–432, 1987
Needs CJ, Brooks PM. Clinical pharmacokinetics of the salicylates. Clinical Pharmacokinetics 10: 164–177, 1985
Netter P, Bannwaith B, Lapicque F, Abiteboul M, Lequintrec JS, et al. Influence of synovial fluid concentrations of ketoprofen on PGE2 and arthritic pain. Abstract. Clinical Pharmacology and Therapeutics 53: 152, 1993
Netter P, Bannwarth B, Royer-Morrot MJ. Recent findings in the pharmacokinetics of non-steroidal anti-inflammatory drugs in synovial fluid. Clinical Pharmacokinetics 17: 145–162, 1989
Ollagnier M, Decousus H, Cherrah Y, Levi F, Mechkouri M, et al. Circadian changes in the pharmacokinetics of oral ketoprofen. Clinical Pharmacokinetics 12: 367–378, 1987
Orme M. NSAIDs in the healthy elderly. In Famaey & Paulus (Eds) Therapeutic applications of NSAIDs, pp. 191–210, Marcel Dekker, New York, 1992
Orme MLE. Plasma concentrations and therapeutic effect of anti-inflammatory and anti-rheumatic drugs. Pharmacology and Therapeutics 16: 167–180, 1992
Owen JA, Sitar DS, Berger L, Brownell L, Duke PC, et al. Age-related morphine kinetics. Clinical Pharmacology and Therapeutics 34: 364–368, 1983
Peyron JG, Altman RD. The epidemiology of osteoarthritis. In Moskowitz et al. (Eds), Osteoarthritis: diagnosis and medical/surgical management, pp. 15–37, WB Saunders, Philadelphia, 1992
Porter RS. Factors determining efficacy of NSAIDs. Drug Intelligence and Clinical Pharmacy 18: 42–51, 1984
Reinberg A, Manfredi R, Kahn MF, Chaouat D, Chaouat Y, et al. Tenoxicam chronotherapy of rheumatoid diseases. Annual Review of Chronopharmacology 7: 293–296, 1990
Rudy AC, Bradley JD, Ryan SI, Kalasinski LA, Xiaotao Q, et al. Variability in the disposition of ibuprofen enantiomers in osteoarthritis patients. Therapeutic Drug Monitoring 14: 464–470, 1992
Runkel R, Forchielli E, Sevelius H, Chaplin M, Segre E. Nonlinear plasma level response to high doses of naproxen. Clinical Pharmacology and Therapeutics 15: 261–266, 1974
Sanders PA, Grennan DM. Non-steroidal anti-inflammatory drugs versus simple analgesics in the treatment of arthritis. Baillière’s Clinical Rheumatology 4: 371–385, 1990
Scatina J, Hicks D, Kraml M, Weidler D, Garg D, et al. Etodolac kinetics in the elderly. Clinical Pharmacology and Therapeutics 39: 550–553, 1986
Smith GL, Goulbourn RA, Burt RAP, Chatfield DH. Preliminary studies of absorption and excretion of benoxaprofen in man. British Journal of Clinical Pharmacology 4: 585–590, 1977
Triggs EJ, Nation RL, Long A, Ashley JJ. Pharmacokinetics in the elderly. European Journal of Clinical Pharmacology 8: 55–62, 1975
Verbeeck RK, Branch RA, Wilkinson GR. Drug metabolites in renal failure: pharmacokinetics and clinical implications. Clinical Pharmacokinetics 6: 329–345, 1981
Wallis WJ, Simkin PA. Anti-rheumatic drug concentration in human synovial fluid and synovial tissue: observation on extravascular pharmacokinetics. Clinical Pharmacokinetics 8: 496–522, 1983
Woodhouse KW, Wynne H. The pharmacokinetics of nonsteroidal anti-inflammatory drugs in the elderly. Clinical Pharmacokinetics 12: 111–122, 1987
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Skeith, K.J., Brocks, D.R. Pharmacokinetic Optimisation of the Treatment of Osteoarthritis. Clin. Pharmacokinet. 26, 233–242 (1994). https://doi.org/10.2165/00003088-199426030-00006
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003088-199426030-00006